I had a chance to speak with a former employee at Locus Pharmaceuticals - where she worked for Mr. Landekic - to get her opinion on his mind set. It was fairly interesting and I wanted to share some things.
First, she said that Mr. Landekic is a really driven and determined person that is excellent at raising funds (she reiterated that several times).
Second, she said that he really got screwed at Locus Pharma when they were acquired by an (Asian or German?) company, who shifted their business model to a CRO (contract research organization). She felt that Mr. Landekic would not let that happen to him again.
She felt that he would not put shareholders' interests ahead of the company; something I feel is contradictory, since the shareholders own the company.
Lastly, she made the point that several researchers left Locus after Mr. Landekic was let go. He was a strong leader and very positive.
All this is fairly congruent with what I have seen with Polymedix. The researchers are excellent and the environment is positive. They seemed to want to keep things in-house and reduce the need to give up too much to an eventual partner; like marketing rights or licensing of their IP.
This is not anything investment advice, but I hope that helps in some way.
General Nic’s Message Sent Just Prior to the Invasion
Stockholder, Sailors and Airmen of the Allied Expeditionary Force! You are about to embark upon a great crusade, toward which we have striven these many months. The eyes of the world are upon you. The hopes and prayers of liberty loving people everywhere march with you. In company with our brave Allies and brothers in arms on other fronts, you will bring about the destruction of the bacteria war machine, the elimination of methicillin-resistant Staphylococcus aureus (MRSA), tyranny over the oppressed peoples of Europe and USA, and security for ourselves in a free world.
Your task will not be an easy one. Your enemy is well trained, well equipped and battle hardened, he will fight savagely.
I think one would be silly to assume Nick with Millions of shares would shoot himself in the foot. I do believe he is being a little overzealous with the RS, should have waited until after phase II announcement.
Actually after reading the "Back story" i was so encouraged that I bought another 5k shares. I see no reason why PYMX cannot be a 2-3billion market cap stock in the next 2-3 years.
The CEO will not sell PYMX and lose control even if he is offered a lot of cash for his shares and a good job with the acquirer. He will not relinquish major rights to 63, which has the potential to introduce a new paradigm in the treatment of infections. This leaves 56. If he can not get a "quality deal" on 56 from BP, he reserves the right to raise cash through dilution and go all the way with 56( which is a quantitative treatment and simpler to evaluate)to phase 3 until he does get a quality deal.